Source: Annual Congress 2006 - Neurogenic inflammation – the link between nervous system and lung dysfunction
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Petkov (Vienna, Austria). Neuropeptides and the pulmonary vasculature. Annual Congress 2006 - Neurogenic inflammation – the link between nervous system and lung dysfunction

Member's Comments

No comment yet.

Related content which might interest you: COVID-19 and the pulmonary circulation Source: ERS webinar 2020: COVID-19 and the pulmonary circulation Year: 2020 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Screening for pulmonary vascular disease (PVD) in patients with portal hypertension by investigating pulmonary hemodynamics during exercise Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Pulmonary hypertension in chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 892-905 Year: 2003 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations Source: Eur Respir Rev 2014; 23: 350-355 Year: 2014 Pulmonary vascular resistances during exercise in normal subjects: a systematic review Source: Eur Respir J 2012; 39: 319-328 Year: 2012 Single arterial occlusion to locate resistance in patients with pulmonary hypertension Source: Eur Respir J 2003; 21: 31-36 Year: 2003 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Exercise stress echocardiography for the study of the pulmonary circulation Source: Eur Respir J 2010; 35: 1273-1278 Year: 2010 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Serotonin transporter genes, pulmonary haemodynamics and pulmonary hypertension Source: Annual Congress 2005 - Scientific year in review Year: 2005 Exercise limitation in idiopathic pulmonary arterial hypertension (IPAH): there‘s more to it than just the pulmonary circulation Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease Source: Eur Respir J 2013; 41: 217-223 Year: 2013 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011